Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies

Completed

• Conditions: Glaucoma

• Registration Number: NCT02151318
• Lead Sponsor: University of South Florida

Brief Summary

In this study, the investigators will collect tissue from patients undergoing trabeculectomy for primary open-angle glaucoma treatment. This tissue would normally be discarded. These trabecular meshwork (TM) cells can be cultured and used experimentally to better understand the mechanisms of glaucoma. These TM biopsies will be cultured on the same day as the trabeculectomy using established techniques.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-05-21
• Study First Submitted QC: 2014-05-27
• Study First Posted: 2014-05-30
• Study Start: 2014-12
• Primary Completion: 2015-07
• Study Completion: 2016-11
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-24
• Last Update Posted: 2024-06-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

• Patients having glaucoma and undergoing a trabeculotomy
• Sign ICF (Informed Consent Form)

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy of new glaucoma medications to reduce TM cellular pathologies associated with the disease glaucoma.	6 weeks	TM cell biopsy samples from patients with glaucoma will be harvested and cultured in a laboratory setting to grow primary human TM cells. These cells will be used to test different medications, looking at the medications ability to reduce cellular pathologies commonly seen in TM tissue of patients with glaucoma. Pathologies include myocilin aggregation, and cell death. This will help researchers to determine the most effective compounds in treating glaucoma.

Secondary Outcome Measures

Name	Time	Method
Cultured TM cell toxicity caused by new glaucoma medications	6 weeks	Cultured primary TM cells treated with various new medications synthesized to treat cellular pathologies associated with glaucoma, will also be analyzed to look at toxicity caused by the treatments themselves. THis will help to determine the safety of these new medications prior to being administered to patients.

Trial Locations

Locations (2)

Byrd Alzheimer's Institute; 🇺🇸 Tampa, Florida, United States

Tampa General Hosipital; 🇺🇸 Tampa, Florida, United States